SOUTH SAN FRANCISCO, Calif., Feb. 1, 2016 /PRNewswire/ -- Tobira Therapeutics, Inc. (NASDAQ: TBRA) today announced that company management will present an overview of the company at the following conferences in February.
- 18th Annual BIO CEO & Investor Conference
- Presentation date: Tuesday, February 9, 2016
- Presentation time: 3:30 p.m. ET
- Leerink Partners 5th Annual Global Healthcare Conference
- Presentation date: Wednesday, February 10, 2016
- Presentation time: 3:55 p.m. ET
A live webcast and 30-day archive of these presentations will be available at http://ir.tobiratherapeutics.com.
About Tobira Therapeutics Tobira is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and HIV. The company's lead product candidate, cenicriviroc (CVC), is a first-in-class immunomodulator and dual inhibitor of CCR2 and CCR5 being evaluated for the treatment of non-alcoholic steatohepatitis (NASH). Learn more about Tobira at www.tobiratherapeutics.com.
Tobira® is a registered trademark owned by Tobira Therapeutics, Inc.
©2016 Tobira Therapeutics, Inc. All Rights Reserved.
Tobira Investor & Media Contact: Ian Clements, Ph.D. +1 (650) 351-5013 firstname.lastname@example.org
Canale Communications Media Contact: Pam Lord +1 (619) 849-6003 email@example.com
SOURCE Tobira Therapeutics, Inc.